DNA Vaccine Delivery - Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors. - BioPharm International

ADVERTISEMENT

DNA Vaccine Delivery
Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors.


BioPharm International Supplements
Volume 24, Issue 10, pp. s12-s18

REFERENCES

1. M.A. Lui, Immunol. Rev. 239, 62–84 (2010).

2. "West Nile-Innovator DNA", Fort Dodge Animal Health. E0257D 15M AP (Nov. 2008).

3. N.C. Simard, "The Road to Licensure of a DNA Vaccine for Atlantic Salmon", http://www.bion.no/filarkiv/2010/07/vaccine_simard.pdf, accessed Aug. 2011.

4. S. Vasan et al., PLoS One 6 (5), e19252 (2011).

5. K.E. Broderick et al., Hum. Vaccines 7, 22–28 (2011).

6. T. Kardos. "Contactless Magnetic Electroporation" presented at the DNA Vaccines Conference (San Diego, CA, 2011).

7. M.R. Prausnitz et al., Microbiol. Immunol. 333, 369–393 (2009).

8. J.W. Hooper et al., Vaccine 25, 1814–1823 (2007).

9. A.K. Roos et al., Mol. Ther. 13 (2), 320–327 (2006).

10. L.A. Hirao et al., J. Infect. Dis. 203 (1), 95–102 (2011).

11. D.J. Laddy et al., J. Virol. 83 (9), 4624–4630 (2009).

12. P.T. Loudon et al., PLoS One 5 (6), PLoS ONE doi:10.1371/journal.pone.0011021, Jun. 8, 2010.

13. M.A. Kutzler and D.B. Weiner, Nature Rev. Genetics 9, 776–788 (2008).

14. M. Shata et al., Mol. Med. Today 6, 66–71 (2000).

15. P.M. Smooker et al., Biotechnol Annual Rev. 10, 189–236 (2004).

16. G. Dietrich, A. Collioud, and S.A. Rothen. Biopharm Intl. 21 (10) s6–s14 (2008).

17. A. Edwards and N.K.H. Slater, Vaccine 27, 3897–3903 (2009).

18. FDA, Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. (Rockville, MD, Sept. 2010).

19. J.M. Huang et al., Vaccine 28, 7523–7528 (2010).

20. J. Bergin, "DNA Vaccines: Technologies and Global Markets," BCC Research (2009)


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here